Reactive Management for Maculopapular Rash

General Recommendation

Prevention includes routine skin care measures as previously described. Maculopapular rash is associated with skin inflammation that leads to Pruritus, which is the focus of symptomatic treatment.1

Treatment Overview

Symptomatic treatment may include an oral antihistamine such as loratadine during the day and a sedative antihistamine such as hydroxyzine 25-50 mg at night.1 In addition, topical antipruritics, such as menthol 0.5-3% or 0.5% pramoxine or doxepin may be applied once or twice daily, after first testing on a small area of skin.1,2 Menthol creams are good options for pruritus relief and may therefore be considered as well. Since some patients experience a burning sensation with them, subjects with dry skin and Fissures should first apply a plain cream to protect the skin.1

For patients with moderate-to-severe maculopapular rash who tolerate menthol cream well, consider the addition of a topical high potency corticosteroid such as clobetasol propionate.1

Among patients receiving regorafenib in two phase III trials, grade 1 to 3 maculopapular rash was successfully managed using antihistamines and a short course of corticosteroid in a cream base (e.g. clobetasol 0.05% in cold cream).3

Oral antiepileptic gabapentin or pregabalin should be used only in exceptional cases of very resistant itch as second-or third-line treatment.2

Patients should be evaluated weekly. With the second or third occurrence of maculopapular rash intensifying supportive measures is advised. If symptoms still worsen despite the intensified measures, interruption or discontinuation of the Multikinase inhibitor should be considered.

Treatment of NCI-CTCAE V4.03 Grade 11,3

  • Oral antihistamine (e.g. loratadine)
  • Menthol cream 0.5-3%

Treatment of NCI-CTCAE V4.03 Grade 21,3

  • As for grade 1
  • Add a topical corticosteroid (e.g. clobetasol 0.05%)

Treatment of NCI-CTCAE V4.03 Grade 31,3

  • As for grade 2
  • Refer to a dermatologist

Products

  • Oral antihistamine (e.g. loratadine)
  • Menthol cream 1-3%
  • Clobetasol 0.05% cream

Multikinase Inhibitor Treatment

Continue with/withhold the selected multikinase inhibitor treatment regimen, as recommended in the current and relevant SPC and according to the patient’s condition.

References

1Boers-Doets CB. The TARGET SYSTEM. Approach to assessment, grading, and management of dermatological & mucosal side effects of targeted anticancer therapies. ISBN 978-94-92070-00-5 2014
2Lacouture ME et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities Support Care Cancer. 2011; 19: 1079-95.
3De Wit M et al. Prevention and management of adverse events related to regorafenib. Support Care Cancer. 2014; 22: 837-46.

Last update: 22 August 2014